TVTX Travere Therapeutics (TVTX) Q1 FY26 earnings call
Travere Therapeutics reported a strong start to the year, marked by the significant FDA approval of FILSPARI for FSGS, which expands its market opportunity. The company also achieved record demand for FILSPARI in IgA nephropathy, demonstrating robust commercial execution. With the Phase III HARMONY study for pegtibatinase reinitiating enrollment, Travere is advancing its pipeline while leveraging established market presence for accelerated growth in rare kidney diseases.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
TVTX operating KPIs by quarter
| KPI | This call Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| New patient start forms FILSPARI | 993The first quarter marked the highest demand to date as we received 993 new patient [ start forms ], reflecting continued expansion among new prescribers and deepening utilization across established accounts.Source: earnings call transcript | 2,000+Their efforts resulted in record FILSPARI demand with over 2,000 new patient start forms across IgA nephropathy and FSGS and record US revenue of more than $141 million for the quarter.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.